We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > REGENT

News List

Regent Pacific Receives HK$24.96 million After Clinical Trial Approval For FORTACIN(TM) Has Been Obtained prnasia
April 02, 2021
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce that the Group has received a payment of US$3.20 million (approximately HK$24.96 million) before deduction of PRC withholding ...
Carmine, Takeda Collaborate to Discover and Develop Rare Disease Gene Therapies americanpharmaceuticalreview
July 09, 2020
Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialize non-viral gene therapies for two rare disease targets using Carmine's REGENT technology, based on red blood cell extracellular vesicles.
Takeda forms $900m research alliance with Carmine Therapeutics pharmaceutical-technology
July 01, 2020
Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of rare disease therapies.